The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype
Gemcitabine (GEM), an antimetabolite that terminates DNA synthesis, is commonly used in the treatment of cancers including lung adenocarcinoma (LUAD). However, downregulation of sensitivity limits the
a The overall mean onset time for all groups is 31.54 (19.50, 85.37).b Pairwise comparison Fisher's exact test p>0.05 AIGIV+levofloxacin vs. placebo+levofloxacin.— No animal died.**Post-treatment bloo
